Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Expected to Post Quarterly Sales of $2.90 Million

Brokerages forecast that Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Rating) will report sales of $2.90 million for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Rhythm Pharmaceuticals’ earnings, with the highest sales estimate coming in at $3.50 million and the lowest estimate coming in at $2.30 million. Rhythm Pharmaceuticals reported […]

Related Keywords

Stifel Nicolaus ,Zacks Investment Research ,Rhythm Pharmaceuticals ,Nasdaq ,Needham Company ,Rhythm Pharmaceuticals Inc ,Goldman Sachs Group ,Canaccord Genuity Group ,Macquarie Group Ltd ,Rhythm Pharmaceuticals Get Rating ,Get Rating ,Rhythm Pharmaceutical ,Investment Research ,Rock Springs Capital Management ,Springs Capital Management ,Nasdaq Rytm ,Rytm ,Medical ,Ratings ,Consensus ,